MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer
October 25 2018 - 8:30AM
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated,
clinical-stage gene therapy company, today announced that on
October 2nd, 2018, it expanded its leadership team with the
appointment of Katherine Breedis as chief financial officer. Prior
to joining MeiraGTx, Ms. Breedis was a managing director, equity
research, and senior analyst for biotechnology and major
pharmaceuticals with Stifel Nicolaus & Company.
“Katherine is an experienced professional with more than 30
years in the financial and pharmaceutical industries, where she
developed strong relationships with the financial community,” said
Alexandria Forbes, Ph.D., president and chief executive officer of
MeiraGTx. “We are pleased to have Katherine join our team and are
confident that her leadership, expertise and insights will help us
grow the company as we advance our broad portfolio of gene
therapies.”
Prior to joining Stifel Nicolaus & Company in 2015, Ms.
Breedis worked for several years in the pharmaceuticals industry.
At Pfizer Inc., she served as senior director, corporate strategy,
providing guidance to the company’s executive leadership team and
board of directors on mergers and acquisitions, business
development, competitive landscape assessments and long-range
corporate strategic planning. Before that, she was senior director,
global external research and development, at Eli Lilly &
Company. Earlier in her career, she held a number of positions in
the financial industry, including first vice president/healthcare
equity analyst at Schroder Investment Management North America;
principal and founder of Teewinot Capital Investors, LLC, where she
focused on equity investments within the specialty/major
pharmaceuticals, biotechnology and medical technology sectors; and
vice president, global investment research, and senior analyst,
specialty pharmaceuticals at Goldman Sachs & Co. Before that,
she held positions at Citigroup Asset Management, General Electric
Capital Corporation, Creditanstalt-Bankverein, Dillon, Read &
Co. and Citibank, N.A.
“I’ve followed and analyzed dozens of biopharma companies as
they have developed innovative therapies and brought them through
clinical development and regulatory approval to commercialization.
I believe MeiraGTx is well-positioned to be a leader in gene
therapy and am especially impressed by MeiraGTx’s expert management
team, broad, potentially best-in-class pipeline and high-quality,
internal cGMP manufacturing capabilities,” said Ms. Breedis. “I’m
excited to be joining the team and look forward to contributing my
financial expertise to help MeiraGTx progress toward its goal of
delivering cures to patients living with devastating diseases.”
Ms. Breedis holds a B.A. in economics and art history from
Wheaton College. She is a chartered financial analyst (CFA) and a
chartered market technician (CMT). She also serves as an advisor to
the Rockefeller University Robertson Therapeutic Development
Fund.
About MeiraGTx MeiraGTx (NASDAQ:MGTX)
is a vertically integrated, clinical stage gene therapy company
with four ongoing clinical programs and a broad pipeline of
preclinical and research programs. MeiraGTx has core
capabilities in viral vector design and optimization and gene
therapy manufacturing, as well as a potentially transformative gene
regulation technology. Led by an experienced management
team, MeiraGTx has taken a portfolio approach by
licensing, acquiring and developing technologies that give depth
across both product candidates and indications. MeiraGTx’s initial
focus is on three distinct areas of unmet medical need: inherited
retinal diseases, severe forms of xerostomia and neurodegenerative
diseases. Though initially focusing on the eye, salivary gland and
central nervous system, MeiraGTx intends to expand its
focus in the future to develop additional gene therapy treatments
for patients suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.
Contacts Investors:
MeiraGTxInvestors@meiragtx.com
Media:W2O Group Christiana Pascale (212)
257-6722cpascale@w2ogroup.com
MeiraGTx (NASDAQ:MGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
MeiraGTx (NASDAQ:MGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024